Navigation Links
Certain pain medications do not appear to be associated with skin cancer risk
Date:2/15/2010

Contrary to previous hypotheses, the use of non-steroidal anti-inflammatory drugs does not appear associated with risk of squamous cell skin cancer, according to a report posted online today that will appear in the April print issue of Archives of Dermatology, one of the JAMA/Archives journals.

Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen and celecoxib reduce pain and inflammation by blocking an enzyme involved in producing inflammatory compounds, according to background information in the article. NSAIDs may also inhibit the development of cancer cells by inducing cells to die and inhibiting the growth of new blood vessels.

Laboratory studies of cells and animals have indicated that NSAIDs protect against squamous cell carcinomas, common types of cancers that appear in the upper layers of the skin. However, while some studies have examined the associations between NSAIDs and other types of cancersincluding colorectal, breast, prostate and lungfew have assessed the association between NSAID use and squamous cell carcinoma risk in human populations.

Maryam M. Asgari, M.D., M.P.H., of Kaiser Permanente Northern California, Oakland, and colleagues studied 415 health plan members who were diagnosed with squamous cell carcinoma in 2004 and 415 control patients who were the same age, [Bleep] and race but had no history of skin cancer. Participants completed a questionnaire about NSAID use in the 10 years prior.

The majority of participants (61 percent) reported regular use of NSAIDs within the previous ten years, including 48 percent who used aspirin, 18 percent who used ibuprofen, 5 percent who used naproxen and 4 percent who used nabumetone.

"Regular use of any NSAID was not associated with a reduction in squamous cell carcinoma risk," the authors write. "Although NSAID users whose exposure was of short duration (one to three years) appeared to be at somewhat increased risk for squamous cell carcinoma, we found no consistent effects of duration of use of any NSAID on squamous cell carcinoma risk." Squamous cell carcinoma risk also did not appear to change regardless of NSAID dose, whether the medications were administered by a pharmacy nor with any individual type of NSAID medication.

"Given the potential toxic effects of NSAIDs, including platelet dysfunction and gastric ulcers, more uniformly efficacious chemopreventive agents with safer adverse effect profiles need to be explored," the authors conclude.


'/>"/>

Contact: Maureen McInaney-Jones
maureen.mcinaney@kp.org
510-891-3173
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Hypertension may predict dementia in older adults with certain cognitive deficits
3. G Marks the Spot: Good Vibrations Proclaims February as National G-Spot Month -- Sex Toy Company Says "It Most Certainly Does Exist!"
4. Mount Sinai finds prenatal exposure to certain chemicals affects childhood neurodevelopment
5. Video Games Could Boost Certain Thinking Skills
6. Swine Flu Wanes, But Future Uncertain
7. Certain Childhood Cancers More Likely to Recur
8. Greater certainty in monitoring 3 therapeutic medications is facilitated by new CRMs
9. Certain Reflux Drugs Tied to Higher Post-Angioplasty Death Rate
10. FDA Authorizes Emergency Use of Intravenous Antiviral Peramivir for 2009 H1N1 Influenza for Certain Patients, Settings
11. Increased success a virtual certainty for rugby players
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... Dr. Barry ... Avenue Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic ... of the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
(Date:12/5/2016)... ... ... has joined the Retina Group of New York (RGONY) specializing in uveitis and ... and has been providing tertiary medical and surgical retinal care on Long Island for over ... peers. Growing up in a family of doctors, Dr. Shah emulated the role of ...
(Date:12/5/2016)... ... December 05, 2016 , ... Houston ... 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine European ... European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, clinicians, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... Swirl: A Wine Tasting Event in New York City, with long-time partners The ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Several leading Alzheimer,s disease experts will participate in ... 11 a.m. EST on December 6 in advance of ... Alzheimer,s Disease (CTAD). The program will include discussions on ... targets that address deficient glucose metabolism observed in Alzheimer,s ... another therapy targeting the amyloid hypothesis, now more than ...
(Date:12/5/2016)... and BOCA RATON, Fla. ... Florida Institute for the Commercialization of Public Research ... has finalized a funding agreement SegAna, LLC, an ... developed at University of Central Florida. The Florida ... research, and bridges early funding gaps for companies ...
(Date:12/5/2016)... , December 5, 2016 According to a ... modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application ... MarketsandMarkets, the market is projected to reach USD 779.8 Million by ... of 13.5% during the forecast period of 2016 to 2021. ... ...
Breaking Medicine Technology: